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Background: Bronchiectasis is characterised by neutrophilic bronchial inflammation and
patients are prone to recurrent or chronic bacterial airway infections. Direct measurement
of lung inflammation would be useful in order to assess disease activity and guide need for anti-
biotic treatment and to monitor response. Current methods of monitoring inflammation are
invasive, indirect or insensitive. Exhaled nitric oxide (FENO) is a direct simple non-invasive test
of inflammation used in other airway diseases. The aim of this study was to test whether
peripheral airway nitric oxide (Calv) can provide a clinically useful direct measure of inflamma-
tion in the lungs of patients with bronchiectasis.
Methods: Fifty three patients with bronchiectasis were studied when clinically stable and
a further 20 patients during an exacerbation of bronchiectasis. FENO was measured by chemi-
luminescence using a NO analyser. Two models of pulmonary exchange dynamics were used to
calculate proximal and peripheral contributions to final FENO concentration.
Results: FENO was elevated in bronchiectasis patients compared to 30 healthy controls
(p < 0.05). Compartmental modelling reveals that this elevation is due to an increase in
peripheral airway NO (bronchiectasis 3.6ppb(2.1), controls 2.7ppb(1.5) p<0.05) whereas prox-
imal airway NO levels are normal (bronchiectasis 777(751)pl/s, controls 582(579)pl/s ns). Calv
relates to disease severity measured by lung function and HRCT scan and correlates with the
quality of life score. There is no change in FENO parameters at exacerbation and following
treatment.
Conclusions: Peripheral airway NO is elevated and reflects disease severity in bronchiectasis
but does not provide information to inform acute treatment decisions.
ª 2011 Elsevier Ltd. All rights reserved.7 351 8337; fax: þ44 207 351 8338.
uk (R. Wilson).
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Patients with bronchiectasis have airway dilatation due to
a structural abnormality of the bronchial wall that leads
to delayed mucociliary clearance and predisposes them to
bacterial infection.1 During an infection, large numbers of
neutrophils are attracted from the bloodstream into the
airway by host and bacterial factors.2 In severe bronchi-
ectasis, infection is often persistent and the inflammatory
response becomes chronic. Longstanding infection and
inflammation can cause further damage that may spread
to healthy bystander lung tissue. The levels of inflamma-
tion in stable state bronchiectasis have been reported to
correlate with a reduction in patient’s quality of life.3
Therefore, monitoring inflammation is an important part
of management of bronchiectasis in order to prevent
disease progression and enhance patients’ quality of life.
Current markers of inflammation in the blood, sputum and
those obtained at bronchoscopy are indirect, variable and
invasive respectively.1
Measurement of exhaled nitric oxide (FENO) may be
a useful way to assess airway inflammation. This test is
rapid, non-invasive and can be repeated regularly. To
date there have been five studies of FENO in bronchiec-
tasis, and these have yielded conflicting results. Horvath
et al and Kharitonov et al both showed raised FENO in
bronchiectasis patients.4,5 In Kharitonov’s study, FENO,
correlated with disease severity as measured by FEV1.
Horvath et al, without data to support their opinion
suggested it was related to low level eosinophilic airway
inflammation. In contrast, separate studies by Tsang
et al,6 Ho et al7 and Narang et al8 have found no signifi-
cant difference in FENO in bronchiectasis subjects,
compared to healthy controls. No study has assessed FENO
during an exacerbation of bronchiectasis when inflam-
mation is increased.
By measuring NO at different expiratory flow rates the
contribution of NO from different parts of the lung can be
assessed. A low flow rate results in an increased diffusion
gradient of NO across the proximal airways and therefore
higher contribution from this area. Two-compartment
models of pulmonary NO exchange dynamics can be used
to demonstrate relative contributions of bronchial (JNO)
and peripheral airway (Calv) NO to the final FENO concen-
tration.9,10 Two different models of NO dynamics have
been proposed. This paper applies these models in bron-
chiectasis, when patients are stable and during an
exacerbation.
Aim
The aims of this study were:
1) To compare bronchial and peripheral airway contri-
bution to FENO in a large group of stable patients with
bronchiectasis compared to healthy controls.
2) To compare NO with disease severity in bronchiectasis
(measured by lung function, HRCT and quality of life).
3) To assess NO as a clinically useful measure of
inflammation during an exacerbation of bronchiectasis
and following treatment.Methods
Study design
This study was approved by the Royal Brompton Hospital
ethics committee. All patients gave informed signed
consent to take part.
NO parameters in consecutively referred patients with
bronchiectasis compared to healthy volunteers
Fifty three consecutive patients with bronchiectasis were
recruited while, they attended the hospital for a program
of tests designed to investigate the cause and severity of
their bronchiectasis. This protocol has been previously
described.11 Patients were asked to perform FENO tests at
variable flow rates. The relative contributions of JNO and
Calv were calculated and the results were compared to
those of thirty healthy controls of similar age and gender.
NO parameters compared to measures of disease severity
NO was compared with lung function and quality of life.
Quality of life was assessed by St George’s Respiratory
Questionnaire (SGRQ), which has been validated in bron-
chiectasis. This questionnaire has 3 components, symp-
toms, activities and impact, which combine to give a total
score. The score ranges from 0 to 100, with 100 indicating
a poor quality of life. A 4 point change is considered clini-
cally significant.12 Lung function and SGRQ were performed
within 3 days of the NO test.
34 of the stable patients had a HRCT performed for
clinical reasons within 3 days of the NO test. The 19
patients who had previously had HRCT and in which
another was not clinically indicated, were not included in
the HRCT part of the analysis. NO was compared with
disease severity on HRCT. HRCT was scored independently
by two radiologists using a modification of the Bhalla score
as previously described.13
Exacerbation study design
FENO at multiple flow rates was measured in 20 patients
within 24 hours of admission to hospital, for an infective
exacerbation of bronchiectasis requiring intravenous anti-
biotics, and again within 24 hours of discharge. Antibiotics
were chosen by a physician who was guided by current or
previous sputum culture sensitivities. The time of discharge
was dependent on the clinical response to treatment. Blood
was collected from patients on the same day as NO
measurement and FENO results were compared with blood
neutrophil counts, Erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP). Ten patients were followed
up in the outpatient clinic after a three month interval,
when clinically stable.
Study subjects
Patients with bronchiectasis were recruited from the
infection firm at the Royal Brompton hospital. Bronchiec-
tasis was confirmed by high resolution CT scan according to
standard criteria.14 Current smokers (smoked within the
two months preceding the study) were excluded as smoking
has been shown to alter FENO.
15 Patients with cystic fibrosis
Table 1 Nitric oxide in patients with bronchiectasis
compared to healthy control subjects
Healthy
controls
Non-PCD
non CF
bronchiectasis
FENO50 (ppb) median (IQR) 13.7 (9.5) 19.4 (13.3)
a
FENO100 (ppb) median (IQR) 8.3 (4.2) 11.0 (7.3)
a
FENO200 (ppb) median (IQR) 5.0 (2.0) 7.2 (3.0)
a
JNO (pl/s) median (IQR) 582 (579) 777 (751)
Calv (ppb) median (IQR) 2.7 (1.5) 3.6 (2.1)
a
ADCalv (ppb) median (IQR) 1.3 (1.4) 2.1 (2.4)
n 30 53
FENOxZ Fractional exhaled nitric oxide measured at x ml/s,
JNOZ Bronchial nitric oxide flux, CalvZ Peripheral airway nitric
oxide calculated using the two compartmental model of NO
exchange, ADCalvZ Peripheral airway nitric oxide calculated
using the axial diffusion model, PCDZ primary ciliary dyski-
nesia, CFZ cystic fibrosis.
a p<0.05 compared to healthy controls.
Peripheral NO severity in bronchietasis 887(CF) and primary ciliary dyskinesia (PCD) and patients
known to have asthma were also excluded as FENO is altered
in these conditions.4 Patients with mild bronchiectasis, but
another predominant aetiology were also excluded.
Average age (SD) of all patients studied was 57 (22) and 29%
were male. Subject demographics were statistically similar
for all groups and subgroups (data not shown). Ten subjects
were ex-smokers (mean 16 pack years).
Thirty non-smoking hospital staff of similar age 42(24)
and gender (27% male) to the bronchiectasis group were
recruited as normal controls. They had been well for at
least 8 weeks and had no relevant medical history.
Experimental tests
NO was measured at 50, 100, and 200 ml/s using a NO
analyser (NiOx, Aerocrine, Sweden). Two measurements
within 10% agreement were performed at each flow rate
according to ATS standards.16 Actual flow, FENO and
ambient NO were recorded for each measurement.
Data analysis
The mean of the two FENO measurements at each flow rate
measured was used to calculate JNO and Calv using the linear
equation of Tsoukias and George two compartmental model
of pulmonary exchange dynamics.9
VNOZJNO þ VE$Calv
VNO [pl/s] is NO output during exhalation (exhaled
NO concentration [ppb]  exhalation flow rate [L/s]),
JNO [pl/s] is total NO flux in the airways, VE [ml/s] is
exhalation flow rate, and Calv [ppb] is steady-state NO
concentration in alveolar air and peripheral airways.
At each expiratory flow (50 ml/s, 100 ml/s and 200 ml/s)
the NO output was calculated as FENO xVE. The slope of this
regression line is the alveolar NO concentration (Calv) and
the intercept is the bronchial NO output (JNO).
Data was also analysed using the axial diffusion model
of NO pulmonary exchange dynamics.10 This model allows
for the trumpet shape of the lung (rather than the lung
being comprised of two separate compartments) and gas
phase axial diffusion of NO from the bronchial section
back into the peripheral airways. The model can be
simplified for the flows used (50e250 ml/s) according to
Table 3 in Ref. 10
Calv Z S-I/530
JNO Z I*1.9
S Z slope of the regression line
I Z intercept of the regression line
The data was evaluated using commercially available
statistical analysis software (SPSS). Differences were
considered to be significant when probability values were
less than or equal to 0.05. Where data was normally
distributed values are reported as mean and standard
deviation. Where data distributions differed from normal,
values are reported as median and variation is reported by
inter-quartile range. The natural log of the value was used
to normalise the data distribution for statistical analysis.A student’s t-test or ANOVA was used to compare groups
and linear regression analysis used to assess relationship
between variables.
Results
Proximal and peripheral nitric oxide in
consecutively referred stable bronchiectasis
patients compared to healthy controls
FENO was elevated in patients as compared to healthy
controls at all three flow rates measured. These results
are shown in Table 1. There was no statistical significant
difference between proximal airway NO levels (JNO)
between patients and controls (p Z 0.51). Calv was higher
in the patient group compared to the control group
(p Z 0.03). A second model was used to give an alter-
native value for peripheral airway NO (ADCalv). ADCalv in
patients was elevated compared to normal controls
although this elevation was not statistically significant
(p Z 0.06).
NO according to assessment of lung function,
quality of life and exercise capacity
Table 2 shows lung function parameters and the percent of
predicted values compared with FENO, JNO, Calv and ADCalv.
Peripheral airway NO increased with worsening lung func-
tion (FEV1, MEF50, VA and RV). This relationship was stron-
gest when the axial diffusion model was used to calculate
peripheral airway NO. The relationship between FEV1%
predicted and ADCalv is shown in Fig. 1. When using the
model for ADCalv to predict peripheral airway NO there was
an additional relationship between ADCalv and TLCO and
percent predicted. In contrast to the peripheral airways the
proximal airway NO decreased with worsening lung function
(FEV1, MEF50 and VA% predicted).
Table 2 Calculated NO parameters compared to measurments of lung function in 53 patients with bronchiectasis.
Median
(IQR)
JNO Calv ADCalv
r p r p r p
FEV1
(% pred)
2.1 (1.4)
82.1 (37.9)
0.32
0.32
0.03
0.02
0.25
L0.34
0.08
0.02
L0.44
L0.45
<0.01
<0.01
MEF50
(%pred)
1.9 (1.9)
46.2 (44.0)
0.36
0.39
0.01
<0.01
L0.37
L0.36
<0.01
0.01
L0.54
L0.53
<0.01
<0.01
TLCO
(%pred)
6.1 (2.5)
75.6 (22.4)
0.15
0.21
0.29
0.15
0.20
0.14
0.16
0.32
L0.41
L0.36
<0.01
0.01
VA
(% pred)
4.3 (1.6)
91.0 (22.2)
0.18
0.33
0.21
0.02
0.17
0.29
0.24
0.05
L0.35
L0.43
0.02
<0.01
KCO
(%pred)
1.4 (0.3)
85.4 (20.5)
0.01
0.17
0.97
0.25
0.18
0.01
0.23
0.98
0.22
0.05
0.13
0.74
RV
(%pred)
2.3 (1.0)
120.0 (31.6)
0.14
0.01
0.36
0.96
0.38
0.21
<0.01
0.16
0.33
0.15
0.02
0.32
JNOZ Bronchial nitric oxide flux, CalvZ Peripheral airway nitric oxide calculated using the two compartmental model of NO exchange,
ADCalvZ Peripheral airway nitric oxide calculated using the axial diffusion model, FEV1Z Forced expiratory volume in one second,
MEF50Z Maximum expiratory flow rate at 50% of vital capacity, TLCOZ Transfer Factor of the Lung for Carbon Monoxide, VAZ Alveolar
volume, KCOZTLCO corrected for VA, RVZResidual volume. Statistically significant results (p<0.05) are shown in bold.
888 A. Shoemark et al.Table 3 shows quality of life measured by SGRQ and
exercise capacity measured by shuttle walking test. There
was a significant decrease in JNO with worsening quality of
life (increased score) on all components. In contrast ADCalv
showed an increase with poorer quality of life. Fig. 2 shows
the relationship between ADCalv and total SGRQ score.
There was no relationship between any NO parameter and
exercise capacity.
Stepwise regression of these parameters showed that
MEF50% predicted is independently associated with Calv,
MEF50% predicted and symptom score are associated with
ADCalv and SGRQ symptom score independently predicts JNO.
NO and disease severity on HRCT
There was a negative correlation between summed scores
of bronchiectasis parameters on HRCT and FEV1. There
tended to be a positive correlation between Calv and
increases in CT scores. Results are shown in Table 4. For Calv
this relationship was statistically significant with extent of
bronchiectasis, airway wall thickening and large airway
mucus plugging. There was also a significant relationship
between large airway mucus plugging and severity of
bronchiectasis and ADCalv. There was no relationship
between JNO and CT scan parameters.Figure 1 Correlation between ADCalv and FEV1 % predicted.NO before and after intravenous antibiotics for an
exacerbation of bronchiectasis
JNO and Calv were measured in 20 patients on admission and
at the end of their course of antibiotics on the last day of
their admission. There was no difference in NO parameters
in patients with an acute exacerbation when results were
compared with those patients who were in a stable state
p Z 0.09 (Data shown in Table 1). In the exacerbated
patients sputum cultures yielded P. aeruginosa (12), S.
pneumoniae (1) and no growth (7). There was a trend
towards decrease in JNO, Calv and ADCalv at discharge, but
this reduction was not statistically significant (p > 0.05).
Results at admission and discharge were respectively JNO
797 pl/s (815), 567 pl/s (373); Calv; 5.7ppb (4.9), 4.2ppb
(2.5); ADCalv 4.2ppb (3.4), 3.1ppb (2.1). The results for Calv
are shown in Fig. 3.
In themajority of patients there is little change in the JNO,
Calv and ADCalv and average change in JNO, Calv and ADCalv was
nodifferent tonormal variationof the tests over threedays in
stable bronchiectasis patients (data not shown). The clinical
notes of the two patients with high values in Calv, JNO and
ADCalv on admission were reviewed and there were no
different features that could be identified.
Repeat NO measurements in exacerbated patients
once they are stable
Ten of the twenty patients had NO parameters measured
again in clinic when they were stable at least three months
after the exacerbation. The remaining 10 patients did not
meet criteria for stability during a clinic visit within 12
months of the exacerbation. There was a trend towards
decreased Calv (pZ 0.09) and ADCalv (pZ 0.06) in patients
once stable but this was not statistically significant and
was not more than the normal variation of the tests over
3 days in stable patients. Results for JNO, Calv and ADCalv at
admission, discharge and at follow up were as follows, mean
Table 3 Measured and calculated NO parameters in comparison to St George’s respiratory questionnaire and exercise capacity
in 53 patients with bronchiectasis.
Median
(IQR)
JNO Calv ADCalv
r p r p r p
SGRQ Symptoms 73.7 (22.7) L0.54 <0.01 0.22 0.15 0.52 <0.01
SGRQ Activities 42.3 (38.0) L0.40 <0.01 0.08 0.61 0.40 <0.01
SGRQ Impact 40.5 (27.9) L0.38 0.01 0.13 0.39 0.36 0.02
SGRQ Total 48.4 (31.3) L0.45 <0.01 0.15 0.33 0.45 <0.01
Exercise capacity (metres) 420 (230) 0.18 0.23 0.01 0.94 0.18 0.23
JNOZ Bronchial nitric oxide flux, CalvZ Peripheral airway nitric oxide calculated using the two compartmental model of NO exchange,
ADCalvZ Peripheral airway nitric oxide using axial diffusion model, SGRQ Z St George’s respiratory questionnaire. Statistically signif-
icant results (p<0.05) are shown in bold.
Peripheral NO severity in bronchietasis 889(SD): JNO 867(1222), 519(414), 638(471); Calv, 5.8(4.7), 4.9
(2.1), 3.6(1.3) and ADCalv 4.1(2.7), 3.9(2.1), 2.4(1.8).
Change in blood inflammatory markers before and
after a course of intravenous antibiotics, in relation
to change in NO
In the 20 patients where NO was measured on admission
and at discharge from hospital blood inflammatory markers
were raised on admission and fell following antibiotic
treatment but this was only significant for ESR. Peripheral
blood neutrophil count on admission and at discharge
respectively were 6.7(3.9), 5.7(3.9) p Z 0.18, CRP (mg/L)
24.4(40.1), 15.1(6.8) pZ 0.43 and ESR (mm/hr) 19.2(15.9),
7.2(6.6) p Z 0.01. CRP was not measured in 3 patients and
ESR was not measured in 6 patients at discharge. There was
no correlation between NO parameters and blood inflam-
matory markers (data not shown).
Discussion
This study shows that FENO is elevated in non-CF, non-PCD
bronchiectasis patients compared to healthy controls at all
flow rates measured. Compartmental modelling reveals this
elevation is due to an increase in peripheral airway NO
whereas proximal airway NO levels are normal. This result
may be expected because in most forms of bronchiectasis
the peripheral airways are seen as the major site of damage
on HRCT and inflammation of the peripheral airways is
associated with disease progression.13 Calv measurements
from bronchiectasis patients in this paper are in keeping
with other disease groups: COPD, allergic alveolitis and
some asthma patients.17e19 Interestingly Calv inFigure 2 Correlation between ADCalv and SGRQ total score.bronchiectasis patients is elevated compared to reports in
CF groups.20,21 Results may be lower in CF due to CFTR
function influencing expression of a NOS isoform.22
In bronchiectasis proximal airway NO decreases with
more obstructed lung function whereas peripheral airway
NO increases. These trends might counteract one another
and explain why in some previous bronchiectasis studies
FENO has not been elevated and no relation to FEV1 has
been found. 4,6e8 In COPD, the relationship between FEV 1
and FENO has also been variable in different studies.
23,24
The finding that JNO is normal in bronchiectasis may also
explain the conflicting results from previous studies into
FENO in bronchiectasis. FENO depends upon the flow rate
used and the balance of proximal and peripheral airway NO
at a particular rate.
The present study shows an elevation of peripheral
airway NO with worsening airflow obstruction. Therefore
NO may be a useful reflection of disease severity since FEV1
correlates with extent and severity of bronchiectasis.13,25
This correlation between FEV1, and disease severity
measured by CT was confirmed in the present study
(Table 4). The main predictor of Calv and ADCalv was the
expiratory flow in the middle of the flow volume loop
(MEF50% pred.). In obstructed patients this represents
airways with smaller diameter than the FEV1. We have also
shown that peripheral airway NO reflects disease severity
on HRCT (extent of disease, severity of disease, airway wall
thickening and large airway mucus plugging). The associa-
tions of peripheral NO parameters and airflow obstruction
and disease severity probably explain the correlations with
quality of life. Impaired health status was associated with
high peripheral NO. Proximal airway NO was negatively
independently related to symptom score. However there
were no associations of NO parameters and exercise
capacity assessed by the shuttle walk tests. This negative
correlation between JNO and symptom score and FEV1 may
be related to mucus in the airways trapping NO.
The largest study of FENO levels in bronchiectasis to date
showed an average FENO of 28.6ppb in 109 bronchiectasis
patients compared with 26.8ppb in normal controls.
Although the flow rate used is not described the high values
from controls compared to other studies suggest it was
50 ml/s or less.6,26 When measurements are taken at a low
flow rate Calv contributes very little in proportion to the
total FENO and JNO is the main component measured, which
may explain this result. Only one study has previously used
compartmental modelling to assess NO in patients with
Table 4 JNO and Calv according to assessment of bronchiectasis on HRCT
JNO Calv ADCalv FEV1 % pred
r p r p r p r p
Extent of bronchiectasis 0.13 0.47 0.34 0.05 0.23 0.31 L0.48 <0.01
Severity of bronchiectasis 0.04 0.26 0.24 0.17 0.35 0.05 L0.41 0.02
Airway wall thickening 0.20 0.26 0.43 0.01 0.32 0.07 L0.65 <0.01
Small airway mucus plugging (nZ25) 0.13 0.47 0.30 0.09 0.30 0.09 L0.45 <0.01
Large airway mucus plugging (nZ29) 0.03 0.85 0.36 0.04 0.39 0.02 L0.47 <0.01
JNOZBronchial nitric oxideflux, CalvZPeripheral airwaynitric oxide calculatedusing the twocompartmentalmodel ofNOexchange,ADCalvZ
Peripheral airway nitric oxide calculated using the axial diffusion model. Statistically significant results (p<0.05) are shown in bold.
890 A. Shoemark et al.bronchiectasis. This revealed in nine patients similar Calv
levels to normal controls and a reduction in JNO levels.
27
Higher flow rates were used for measurement in the study
carried out by Foley et al. compared to the present paper
and this could have been responsible for the difference in
results.28 Foley et al also excluded from their studies
patients with pseudomonas infection and patients who had
had a recent infection. Since pseudomonas infection is
associated with more severe disease, inclusion of patients
with less severe disease might have led to lower values
of Calv.
Care should be taken when comparing different studies
as methodology is variable, and the calculation of Calv
requires that some assumptions are made about the
exchange dynamics of the lungs.28 A simplification of the
two compartmental model is that axial diffusion of NO in
the gas phase as a mechanism of transport of NO is
neglected. It has been demonstrated theoretically that if
a substantial source of NO arises in the small airways,
neglecting axial diffusion may cause the two-compartment
model to significantly underestimate the flux of NO from
the airways due to back diffusion into the alveolar region.
The small airways are an important site of inflammation in
bronchiectasis and therefore NO production. This assump-
tion of the model was therefore addressed by performing
a second analysis on all data using the axial diffusion
model. Possibly neither model is accurate at modelling the
bronchiectatic lung where structure and function is grossly
altered compared to a healthy individual. The ADCalv model
appears to over compensate for the back diffusion and inFigure 3 Calv in 20 patients with bronchiectasis on admission
to hospital and after a course of intravenous antibiotics for an
exacerbation (p Z 0.13).several cases gave negative values for ADCalv, which are not
possible. Perhaps back diffusion in the damaged airway is
reduced because the ‘trumpet’ is a different shape influ-
enced by dilated bronchiectatic airways and smaller
airways which are often plugged with mucus. Conversely
the use of a 50 ml/s flow rate for the calculation of Calv can
provide a poor linear fit to the two compartmental model
and may lead to overestimated values of Calv. Ideally
a higher flow rate would be used such as 300 ml/s, unfor-
tunately patients with compromised lung function find
higher flows difficult to achieve. Because the two models
used give different results, we suggest that both should be
used in future studies until a more accurate model can be
found.
In the present study we report little change in FENO
parameters at exacerbation and following treatment,
which shows that whilst peripheral airway NO is raised in
bronchiectasis it cannot be used to monitor inflammation
nor to assess need for antibiotics and response to
treatment.
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